Compare TNET & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | IOVA |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2000 | 2008 |
| Metric | TNET | IOVA |
|---|---|---|
| Price | $42.84 | $3.40 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $65.80 | $9.00 |
| AVG Volume (30 Days) | 336.0K | ★ 14.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $5,010,000,000.00 | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | $3.30 | $40.31 |
| P/E Ratio | $21.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.67 | $1.67 |
| 52 Week High | $86.78 | $5.63 |
| Indicator | TNET | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 57.78 | 44.13 |
| Support Level | $34.47 | $3.23 |
| Resistance Level | $46.38 | $4.27 |
| Average True Range (ATR) | 2.28 | 0.25 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 59.76 | 13.07 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.